Pregnancy after breast cancer in BRCA1/2 mutation carriers

BACKGROUND: Often young women affected with BRCA1/2 positive breast cancer have not finished or even not started their childbearing before the onset of the disease. The aim of our mini-review is to summarize state of art knowledge on pregnancy after breast cancer in BRCA1/2 carriers. METHODS: A broa...

Descripción completa

Detalles Bibliográficos
Autores principales: Maksimenko, Jelena, Irmejs, Arvīds, Gardovskis, Jānis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781048/
https://www.ncbi.nlm.nih.gov/pubmed/35062994
http://dx.doi.org/10.1186/s13053-022-00209-1
_version_ 1784637993523347456
author Maksimenko, Jelena
Irmejs, Arvīds
Gardovskis, Jānis
author_facet Maksimenko, Jelena
Irmejs, Arvīds
Gardovskis, Jānis
author_sort Maksimenko, Jelena
collection PubMed
description BACKGROUND: Often young women affected with BRCA1/2 positive breast cancer have not finished or even not started their childbearing before the onset of the disease. The aim of our mini-review is to summarize state of art knowledge on pregnancy after breast cancer in BRCA1/2 carriers. METHODS: A broad review of the literature was conducted using MEDLINE (via PubMed) for relevant articles published. MAIN BODY OF THE ABSTRACT: This review summarizes the impact of different cytotoxic agents on a fertility, fertility preservation, maternal and fetal prognosis after pregnancy in breast cancer survivors with BRCA1/2. CONCLUSION: According to the existing literature evidence pregnancy after therapy for breast cancer in BRCA carriers is safe for the mother and offspring, but patients’ needs, oncofertility counseling and fertility-sparing strategy should be carefully planned before starting the cytotoxic treatment.
format Online
Article
Text
id pubmed-8781048
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87810482022-01-21 Pregnancy after breast cancer in BRCA1/2 mutation carriers Maksimenko, Jelena Irmejs, Arvīds Gardovskis, Jānis Hered Cancer Clin Pract Review BACKGROUND: Often young women affected with BRCA1/2 positive breast cancer have not finished or even not started their childbearing before the onset of the disease. The aim of our mini-review is to summarize state of art knowledge on pregnancy after breast cancer in BRCA1/2 carriers. METHODS: A broad review of the literature was conducted using MEDLINE (via PubMed) for relevant articles published. MAIN BODY OF THE ABSTRACT: This review summarizes the impact of different cytotoxic agents on a fertility, fertility preservation, maternal and fetal prognosis after pregnancy in breast cancer survivors with BRCA1/2. CONCLUSION: According to the existing literature evidence pregnancy after therapy for breast cancer in BRCA carriers is safe for the mother and offspring, but patients’ needs, oncofertility counseling and fertility-sparing strategy should be carefully planned before starting the cytotoxic treatment. BioMed Central 2022-01-21 /pmc/articles/PMC8781048/ /pubmed/35062994 http://dx.doi.org/10.1186/s13053-022-00209-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Maksimenko, Jelena
Irmejs, Arvīds
Gardovskis, Jānis
Pregnancy after breast cancer in BRCA1/2 mutation carriers
title Pregnancy after breast cancer in BRCA1/2 mutation carriers
title_full Pregnancy after breast cancer in BRCA1/2 mutation carriers
title_fullStr Pregnancy after breast cancer in BRCA1/2 mutation carriers
title_full_unstemmed Pregnancy after breast cancer in BRCA1/2 mutation carriers
title_short Pregnancy after breast cancer in BRCA1/2 mutation carriers
title_sort pregnancy after breast cancer in brca1/2 mutation carriers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781048/
https://www.ncbi.nlm.nih.gov/pubmed/35062994
http://dx.doi.org/10.1186/s13053-022-00209-1
work_keys_str_mv AT maksimenkojelena pregnancyafterbreastcancerinbrca12mutationcarriers
AT irmejsarvids pregnancyafterbreastcancerinbrca12mutationcarriers
AT gardovskisjanis pregnancyafterbreastcancerinbrca12mutationcarriers

Ejemplares similares